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EDITORIAL
Universal health coverage (UHC) has become a 
comprehensive global aspiration, and many countries 
have now committed to processes to deliver it.[1] In 
pursuit of realising this objective, it will be crucial to 
find ways to contend with the tensions between supply 
of and demand for quality services, as well as effective interventions in 
health systems with finite budgets. In doing so, trade-offs are inevitable 
and the need to set priorities becomes crucial.
The World Health Assembly Resolution (67.23) of 2014, to which 
South Africa (SA) is a signatory, is entitled ‘Health Intervention and 
Technology Assessment in Support of Universal Health Coverage’.[2] 
It identifies the ‘critical role of independent health intervention and 
technology assessment’ in generating evidence to inform prioritisation, 
selection, introduction, distribution and management of interventions 
for health promotion, disease prevention, diagnosis and treatment, 
rehabilitation and palliation.[2]
SA has pledged to deliver UHC over two decades through the 
mechanism of National Health Insurance (NHI).[3] Its governance 
and the mechanism of its financing are still under consideration, 
but NHI pilot districts have been identified and work in these has 
begun. One aspect of the NHI policy that has received little attention 
is ensuring that everyone has access to a ‘defined comprehensive 
package of healthcare services’.[3] There are few, if any, countries that 
can provide complete coverage of quality services, whether preventive 
or curative, to every citizen, so addressing the comprehensiveness of 
a package in SA is a pressing issue.
The Lancet Commission on Investing in Health has recommended 
‘progressive universalism’ as a means to achieving UHC.[4] Some 
countries have begun the process with a minimum package that 
is increasing incrementally over time,[5] while others have defined 
a comprehensive healthcare service package that is available for a 
subset of the public at first and subsequently expanded to other 
subpopulations.[6] While currently implicit in SA, a more explicit 
transparent and evidence-informed approach is needed with regard 
to which services and technologies might realistically be covered or 
not. Without this understanding we will not achieve the best value 
for healthcare spending, nor is NHI likely to successfully address our 
severely unequal society, with life expectancies and health-related 
qualities of life much below what they could be.
Policy-makers faced with similar challenges around the world are 
increasingly adopting instruments and mechanisms that overtly define 
the technologies and health services covered and reimbursed by public or 
private entities.[7] These include medicines lists, health benefit plans and 
health technology assessment (HTA).[7,8] HTA has been implemented 
formally by several high-income countries where UHC exists, and is 
increasingly being adopted in low- and middle-income settings.[7]
There are several criteria to use in making decisions about what 
elements that link to equity to include in the package, and how to include 
them – cost-effectiveness thresholds, feasibility of implementation 
and burden of disease, among others. Techniques for combining 
these disparate elements can be challenging, some of them related to 
uncertainties regarding data and evidence. In this respect, learning from 
other settings is important, while ensuring that due consideration is 
given to the country-specific historical, political and social context.[9,10]
In addition, it is widely recognised that wide and transparent 
stakeholder engagement on issues of decision-making and prioritisation 
is key to the success of these processes, with authorities setting out 
guidelines aimed at encouraging participation from the public, patient 
groups, healthcare providers and the medicines and devices industry.[11,12]
Institutionalising decision-making 
and priority-setting
The SA National Health Act of 2003 places the responsibility for 
equitable prioritisation of health services provided by the state with 
the Minister of Health and the Director-General, who are tasked 
to ‘identify national health goals and priorities and monitor the 
progress of their implementation’.[13] The Minister’s prioritisation 
process is to be informed by the National Health Council, which is 
also supposed to advise the Minister on ‘development procurement 
and use of health technology’.[13] At the subnational level, provincial 
health councils are to advise provincial executive committees on the 
same issues.[13]
The trend internationally seems to be one of increased institution-
alisation of HTA and decision-making bodies.[14] HTA agencies have 
developed in several middle-income countries in South-East Asia, 
Latin America and Central Europe. They take various forms, but 
have generally been empowered to generate and apply evidence in a 
consultative process and either to advise on or make resource allocation 
decisions for the health systems in which they operate. The successes 
of institutions such as the Health Intervention and Technology 
Assessment Program (HITAP) in Thailand[15] and development of their 
counterparts in other South-East Asian countries in support of UHC 
have highlighted several models to consider for others embarking on 
this journey.[16-18] In many cases these agencies are directly affiliated to, 
but at arms’ length from, their ministries of health. This has the benefit 
of distancing ministers from potentially unpopular decisions while also 
reinforcing the professional independence of the agency.
Taking up the cause
In March 2015, the first meeting of the International Decision 
Support Initiative (iDSI) in Africa was held at the School of Public 
Health at the University of the Witwatersrand, Johannesburg, SA. 
The iDSI (http://www.idsihealth.org/), established in 2013, is a global 
partnership of leading government institutes, universities and think 
tanks, including NICE International (the National Institute for Health 
and Care Excellence) in England and Wales, HITAP, PRICELESS SA 
(Priority Cost-Effective Lessons for System Strengthening) (www.
pricelesssa.ac.za), the Center for Global Development in Washington, 
DC, and the universities of York in England and Glasgow in Scotland, 
to support policy makers in priority-setting for UHC. The mission of 
the collaboration is to guide decision makers to effective and efficient 
healthcare resource allocation strategies for improving people’s health.
The iDSI supports low- and middle-income governments 
in considering how to formulate resource allocation decisions for 
healthcare. Specifically, the initiative aims to share experiences, 
showcase lessons learned and identify practical ways to scale up 
technical support for systematic, fair and evidence-informed priority-
setting processes. Strengthening priority-setting institutions will 
enhance access to effective health interventions, and the quality and 
efficiency of healthcare delivery. Most importantly, it helps elevate the 
value of priority-setting as essential for attaining and sustaining UHC.
The first meeting brought together some 70 stakeholders to 
begin to identify ways of scaling up practical support for more 
systematic, fair and evidence-informed healthcare priority-setting 
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for all South Africans. Delegates included senior government officials 
and policy makers from the Department of Health and the Treasury, 
development partners, statutory bodies, the private sector (medical 
schemes, pharmaceuticals and devices), researchers and leaders in 
priority-setting from the UK, Thailand and Zambia.
The focus of discussions was to learn from the experience of priority-
setting in SA and abroad and to identify the current range and depth of 
available technical capacity to support priority-setting and to strengthen 
such capacity. A health technology was defined in the broadest sense as 
‘an intervention that may be used to promote health, to prevent, diagnose 
or treat acute or chronic disease, or for rehabilitation’. The term HTA 
is often confined to pharmaceuticals and devices, but can also include 
clinical guidelines and organisational systems used in healthcare.[19]
Current priority-setting in SA
While not always transparent, some public and private sector groups 
are already using HTA and economic evaluation in SA for priority-
setting and decision-making processes.
Several research units based at academic and self-funded 
institutions are already conducting research and providing training 
in economic evaluation and pharmacoeconomic assessment. The 
Directorate of Affordable Medicines in the National Department 
of Health recognises the importance of economic evaluation and 
has included it as one of the criteria for their processes for essential 
medicines selection. The recently published tertiary and quaternary 
essential medicines list suggests that these specialised medicines 
have been scrutinised, but the rationale for positive or negative 
recommendations is not explicit.[20]
The Council for Medical Schemes, which regulates the private 
medi cal schemes, is endeavouring to incorporate aspects of HTA in its 
decision-making for benefit design and protocols for reim bursement.[21]
Much of the economic evaluation research work in SA has 
focused on the curative aspects of the HIV/AIDS and tuberculosis 
epidemics, but it is increasingly expanding to four other priority 
areas: maternal and child health,[22] reproductive health,[23] injury, and 
non-communicable disease.[24]
It is not clear to what extent any of these analyses are utilised 
in resource allocation decisions. Without institutionalising and 
formalising processes to inform such decisions, the current approach 
can perversely impact on capacity, resources and government ability 
to spend its healthcare and prevention budget. Strong stewardship 
could assist in co-ordinating and guiding activities to address the 
policy demand for good-quality evidence for decision-making.
Supported by the iDSI, the PRICELESS SA programme at the Wits 
School of Public Health is investigating existing functions, processes 
and capacity available for priority-setting mechanisms and health 
technology assessment in SA to determine ways to improve the 
adoption and use of critical appraisal and analytics, and the evidence 
they generate, for policy-making.
Conclusion
SA could achieve better value for money in its healthcare services. 
Plans to reform the system have implications for affordability, as 
salaries increase and new technologies and medications come on 
line. Consideration of health system constraints, cost-effectiveness of 
programmes and preventive interventions and the full assessment of 
new and existing technologies through a democratic process should 
form the basis of a priority-setting function to advise the Department 
of Health on the incorporation of these into its future UHC plans. 
With evidence mounting that implementation of UHC can be a costly 
exercise, informed priority-setting will be key to ensuring that public 
financing for health is used effectively, efficiently and equitably.
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